Profile: Meindert Boysen On What Companies Should Expect From NICE And The Benefits Of Hill Walking
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
You may also be interested in...
Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.